153 related articles for article (PubMed ID: 18063884)
1. Efficacy of intravitreal triamcinolone acetonide for eyes with postvitrectomy diabetic vitreous hemorrhage.
Lee SY; Lee HG; Chung HW; Yoon YH; Kim JG
Korean J Ophthalmol; 2007 Dec; 21(4):208-12. PubMed ID: 18063884
[TBL] [Abstract][Full Text] [Related]
2. Intravitreal triamcinolone acetonide in eyes with recurrent postvitrectomy diabetic vitreous hemorrhage.
Lee SY; Yoon YH; Lee HG; Chung H; Kim JG
Am J Ophthalmol; 2006 Sep; 142(3):501-3. PubMed ID: 16935603
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal injection of bevacizumab and triamcinolone acetonide at the end of vitrectomy for diabetic vitreous hemorrhage: a comparative study.
Park DH; Shin JP; Kim SY
Graefes Arch Clin Exp Ophthalmol; 2010 May; 248(5):641-50. PubMed ID: 20012643
[TBL] [Abstract][Full Text] [Related]
4. Intravitreal triamcinolone acetonide injection at the end of vitrectomy for diabetic vitreous hemorrhage: a randomized, clinical trial.
Faghihi H; Taheri A; Farahvash MS; Esfahani MR; Rajabi MT
Retina; 2008 Oct; 28(9):1241-6. PubMed ID: 18626423
[TBL] [Abstract][Full Text] [Related]
5. Ghost cell glaucoma after intravitreal bevacizumab for postoperative vitreous hemorrhage following vitrectomy for proliferative diabetic retinopathy.
Liu L; Wu WC; Yeung L; Wang NK; Kuo YH; Chao AN; Chen KJ; Chen TL; Lai CC; Hwang YS; Chen YP
Ophthalmic Surg Lasers Imaging; 2010; 41(1):72-7. PubMed ID: 20128573
[TBL] [Abstract][Full Text] [Related]
6. Effect of intravitreal triamcinolone acetonide injection at the end of vitrectomy for vitreous haemorrhage related to proliferative diabetic retinopathy.
Takamura Y; Shimura M; Katome T; Someya H; Sugimoto M; Hirano T; Sakamoto T; Gozawa M; Matsumura T; Inatani M;
Br J Ophthalmol; 2018 Oct; 102(10):1351-1357. PubMed ID: 29343528
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal triamcinolone for treatment of complicated proliferative diabetic retinopathy and proliferative vitreoretinopathy.
Munir WM; Pulido JS; Sharma MC; Buerk BM
Can J Ophthalmol; 2005 Oct; 40(5):598-604. PubMed ID: 16391623
[TBL] [Abstract][Full Text] [Related]
8. Reasons for and management of postvitrectomy vitreous hemorrhage in proliferative diabetic retinopathy.
Yan H; Cui J; Lu Y; Yu J; Chen S; Xu Y
Curr Eye Res; 2010 Apr; 35(4):308-13. PubMed ID: 20373898
[TBL] [Abstract][Full Text] [Related]
9. The effect of adjunctive intravitreal conbercept at the end of diabetic vitrectomy for the prevention of post-vitrectomy hemorrhage in patients with severe proliferative diabetic retinopathy: a prospective, randomized pilot study.
Jiang T; Gu J; Zhang P; Chen W; Chang Q
BMC Ophthalmol; 2020 Feb; 20(1):43. PubMed ID: 32013913
[TBL] [Abstract][Full Text] [Related]
10. Management of postvitrectomy diabetic vitreous hemorrhage with tissue plasminogen activator (t-PA) and volume homeostatic fluid-fluid exchanger.
Wu WC; Chang SM; Chen JY; Chang CW
J Ocul Pharmacol Ther; 2001 Aug; 17(4):363-71. PubMed ID: 11572467
[TBL] [Abstract][Full Text] [Related]
11. Repeated intravitreal high-dosage injections of triamcinolone acetonide for diffuse diabetic macular edema.
Jonas JB; Spandau UH; Kamppeter BA; Vossmerbaeumer U; Harder B; Sauder G
Ophthalmology; 2006 May; 113(5):800-4. PubMed ID: 16530840
[TBL] [Abstract][Full Text] [Related]
12. [Triamcinolone in the treatment of the diabetic macular edema--one-year results].
Dusová J; Studnicka J; Rencová E; Korda V; Hejcmanová D
Cesk Slov Oftalmol; 2008 Jul; 64(4):149-52. PubMed ID: 18780654
[TBL] [Abstract][Full Text] [Related]
13. Posterior subtenon and intravitreal triamcinolone acetonide for diabetic macular edema.
Ozdek S; Bahçeci UA; Gürelik G; Hasanreisoğlu B
J Diabetes Complications; 2006; 20(4):246-51. PubMed ID: 16798476
[TBL] [Abstract][Full Text] [Related]
14. Opaque coating of an intraocular lens and regression of iris neovascularization following injection of triamcinolone acetonide into the anterior chamber.
Chen SD; Chen FK; Patel C
Clin Exp Ophthalmol; 2006 Nov; 34(8):803-5. PubMed ID: 17073911
[TBL] [Abstract][Full Text] [Related]
15. Comparison of intravitreal versus posterior sub-Tenon's capsule injection of triamcinolone acetonide for diffuse diabetic macular edema.
Cardillo JA; Melo LA; Costa RA; Skaf M; Belfort R; Souza-Filho AA; Farah ME; Kuppermann BD
Ophthalmology; 2005 Sep; 112(9):1557-63. PubMed ID: 16019075
[TBL] [Abstract][Full Text] [Related]
16. Intravitreal triamcinolone acetonide as an additional tool in pars plana vitrectomy for proliferative diabetic retinopathy.
Jonas JB; Söfker A; Degenring R
Eur J Ophthalmol; 2003 Jun; 13(5):468-73. PubMed ID: 12841570
[TBL] [Abstract][Full Text] [Related]
17. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
Ding X; Li J; Hu X; Yu S; Pan J; Tang S
Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
[TBL] [Abstract][Full Text] [Related]
18. Two-year results of intravitreal triamcinolone acetonide injection for the treatment of diabetic macular edema.
Batioğlu F; Ozmert E; Parmak N; Celik S
Int Ophthalmol; 2007 Oct; 27(5):299-306. PubMed ID: 17453151
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal bevacizumab for prevention of early postvitrectomy hemorrhage in diabetic patients: a randomized clinical trial.
Ahmadieh H; Shoeibi N; Entezari M; Monshizadeh R
Ophthalmology; 2009 Oct; 116(10):1943-8. PubMed ID: 19699531
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal versus posterior subtenon injection of triamcinolone acetonide for diabetic macular edema.
Choi YJ; Oh IK; Oh JR; Huh K
Korean J Ophthalmol; 2006 Dec; 20(4):205-9. PubMed ID: 17302204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
